The purpose of this study was to evaluate the efficacy and compliance of tailored therapy which using the polymerase chain reaction for point mutation of clarithromycin, compared to concomitant therapy, in patients without history of H. pylori eradication.
Name: Lansoprazole 30mg
Description: lansoprazole 30 mg tabletType: Drugconcomitant group tailored treatment group I tailored treatment group II
Name: Amoxicillin 1.0g Tab
Description: Amoxicillin 1.0g tabletType: Drugconcomitant group tailored treatment group I
Name: Clarithromycin 500mg
Description: Clarithromycin 500mg tabletType: Drugconcomitant group tailored treatment group I tailored treatment group II
Name: Metronidazole 500 mg
Description: Metronidazole 500 mg tabletType: Drugconcomitant group tailored treatment group II
Description: Comparison of percentage of people who succeeded in H. pylori eradication among all participants in each treatment group (tailored therapy vs concomitant therapy)
Measure: Comparison of success rate of H. pylori eradication between tailored therapy and concomitant therapy. Time: At 4 weeks after the completion of drug administration, the urea breath test is performed to check for eradication, Before the urea breath test, the proton pump inhibitor or H2 blocker should be discontinued for 2 weeks.Description: Identify the effect of 23S ribosomal RNA point mutation on the eradication rate regardless of the administration drug.
Measure: Difference in eradication rate according to the frequency of 23S ribosomal RNA point mutation in clarithromycin Time: Before the treatment, 23S ribosomal RNA point mutation is confirmed and at least 4 weeks after the end of treatment, urea breath test is performed to check whether or not eradication is completed.Description: After taking the treatment drug, take out all remaining medicine in the outpatient clinic room, check the number of remaining medicines, and judge compliance.
Measure: Number of remaining medicines of tailored therapy compared to concomitant therapy Time: At 4 weeks after the completion of drug administration, when the patient visited for the urea breath test, check the number of remaining medicines.Allocation: Randomized
Parallel Assignment
There are 2 SNPs
Method> Patients with H. pylori infection who have been screened for a 23S ribosomal RNA point mutation (A2142G, A2143G point mutation) and randomized to a concomitant treatment group and a tailored treatment group. --- A2142G ---
Method> Patients with H. pylori infection who have been screened for a 23S ribosomal RNA point mutation (A2142G, A2143G point mutation) and randomized to a concomitant treatment group and a tailored treatment group. --- A2142G --- --- A2143G ---